ERBB2 and breast carcinoma: The over-expression and/or amplification of the HER2 receptor have been associated with aggressive clinical behaviour; nevertheless, the accurate assessment of the HER2 receptor has proven to be essential for identifying breast cancer patients who will benefit from HER2-targeted therapy [4].